Antiretroviral treatment of HIV infection: Swedish recommendations 2007

Scandinavian Journal of Infectious Diseases

Volumn 39, Issue 6-7, 2007, Pages 486-507

  Josephson, Filip ^a   Albert, Jan ^b   Flamholc, Leo ^c   Gisslén, Magnus ^d   Karlström, Olof ^e,f   Lindgren, Susanne Rosa ^f   Navér, Lars ^f   Sandström, Eric ^f   Svedhem Johansson, Veronica ^f   Svennerholm, Bo ^g   Sönnerborg, Anders ^a,f  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Department of Infectious Diseases ^*  (Sweden)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

^f STOCKHOLM SÖDER HOSPITAL   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CELSENTRI; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MK 0518; NELFINAVIR; NEVIRAPINE; PREZISTA; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSENSUS; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPOTENSION; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPOATROPHY; LIVER DYSFUNCTION; LIVER INJURY; LYMPHADENOPATHY; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; MONOTHERAPY; MOTHER CHILD RELATION; MUCOSA INFLAMMATION; MYCOBACTERIOSIS; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PUBLICATION; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SUBCUTANEOUS FAT; SUPERINFECTION; TOXIC EPIDERMAL NECROLYSIS; TUBERCULOSIS; VIREMIA; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; SWEDEN;

EID: 34347370522     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701383154     Document Type: Review

References (106)

1. Shafer, RW, Smeaton, LM, Robbins, GK, De Gruttola, V., Snyder, SW and D'Aquila, RT (2003) Comparison of 4-drug regimens and pairs of sequential 3-drug regimens as initial therapy for HIV-1 infection. N Engl J Med, 349, pp. 2304-2315.
2. Gulick, RM, Ribaudo, HJ, Shikuma, CM, Lalama, C., Schackman, BR and Meyer, WA III (2006) Three- vs 4-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial. JAMA, 296, pp. 769-781.
3. DeJesus, E., Herrera, G., Teofilo, E., Gerstoft, J., Buendia, CB and Brand, JD (2004) Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis, 39, pp. 1038-1046.
4. Bartlett, JA, Johnson, J., Herrera, G., Sosa, N., Rodriguez, A. and Liao, Q. (2006) Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr, 43, pp. 284-292.
5. Eron Jr, J., Yeni, P., Gathe Jr, J., Estrada, V., DeJesus, E. and Staszewski, S. (2006) The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomized non-inferiority trial. Lancet, 368, pp. 476-482.
6. Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C. and Mallal, S. (2006) Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis, 43, pp. 99-102.
7. Pozniak, AL, Gallant, JE, DeJesus, E., Arribas, JR, Gazzard, B. and Campo, RE (2006) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virological, immunological, and morphological changes: A 96-week analysis. J Acquir Immune Defic Syndr, 43, pp. 535-540.
8. Havlir, DV, Tierney, C., Friedland, GH, Pollard, RB, Smeaton, L. and Sommadossi, JP (2000) In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis, 182, pp. 321-325.
9. Gallant, JE, Rodriguez, AE, Weinberg, WG, Young, B., Berger, DS and Lim, ML (2005) Early virological non-response to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis, 192, pp. 1921-1930.
10. Leon, A., Mallolas, J., Martinez, E., De Lazzari, E., Pumarola, T. and Larrousse, M. (2005) High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir. Aids, 19, pp. 1695-1697.
11. Robbins, GK, De Gruttola, V., Shafer, RW, Smeaton, LM, Snyder, SW and Pettinelli, C. (2003) Comparison of sequential 3-drug regimens as initial therapy for HIV-1 infection. N Engl J Med, 349, pp. 2293-2303.
12. Baylor, MS and Johann-Liang, R. (2004) Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr, 35, pp. 538-539.
13. Stocrin, SPC
14. Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G. and Ruane, P. (2002) Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med, 346, pp. 2039-2046.
15. Kempf, DJ, King, MS, Bernstein, B., Cernohous, P., Bauer, E. and Moseley, J. (2004) Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis, 189, pp. 51-60.
16. Johnson, M., Grinsztejn, B., Rodriguez, C., Coco, J., DeJesus, E. and Lazzarin, A. (2005) Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. Aids, 19, pp. 685-694.
17. Kuritzkes, DR. (2003) Preventing and managing resistance in the clinical setting. J Acquir Immune Defic Syndr, 34, p. S103.
18. Beerenwinkel, N., Daumer, M., Sing, T., Rahnenfuhrer, J., Lengauer, T. and Selbig, J. (2005) Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis, 191, pp. 1953-1960.
19. Hirsch, MS, Brun-Vezinet, F., Clotet, B., Conway, B., Kuritzkes, DR and D'Aquila, RT (2003) Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis, 37, pp. 113-128.
20. Vandamme, AM, Sonnerborg, A., Ait-Khaled, M., Albert, J., Asjo, B. and Bacheler, L. (2004) Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther, 9, pp. 829-848.
21. Rizzardi, GP, De Boer, RJ, Hoover, S., Tambussi, G., Chapuis, A. and Halkic, N. (2000) Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest, 105, pp. 777-782.
22. Furrer, H., Egger, M., Opravil, M., Bernasconi, E., Hirschel, B. and Battegay, M. (1999) Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med, 340, pp. 1301-1306.
23. El-Sadr, WM, Burman, WJ, Grant, LB, Matts, JP, Hafner, R. and Crane, L. (2000) Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med, 342, pp. 1085-1092.
24. Jouan, M., Saves, M., Tubiana, R., Carcelain, G., Cassoux, N. and Aubron-Olivier, C. (2001) Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. Aids, 15, pp. 23-31.
25. Mussini, C., Pezzotti, P., Govoni, A., Borghi, V., Antinori, A. and Monforte, A d'Arminio (2000) Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type 1-infected patients: The changes in opportunistic prophylaxis study. J Infect Dis, 181, pp. 1635-1642.
26. El-Sadr, WM, Lundgren, JD, Neaton, JD, Gordin, F., Abrams, D. and Arduino, RC (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med, 355, pp. 2283-2296.
27. Nettles, RE, Kieffer, TL, Kwon, P., Monie, D., Han, Y. and Parsons, T. (2005) Intermittent HIV-1 viraemia (blips) and drug resistance in patients receiving HAART. JAMA, 293, pp. 817-829.
28. Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D. and Collis, P. (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis, 171, pp. 1411-1419.
29. Richman, DD, Havlir, D., Corbeil, J., Looney, D., Ignacio, C. and Spector, SA (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol, 68, pp. 1660-1666.
30. Deeks, SG, Hoh, R., Neilands, TB, Liegler, T., Aweeka, F. and Petropoulos, CJ (2005) Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis, 192, pp. 1537-1544.
31. Castagna, A., Danise, A., Menzo, S., Galli, L., Gianotti, N. and Carini, E. (2006) Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). Aids, 20, pp. 795-803.
32. Hicks, CB, Cahn, P., Cooper, DA, Walmsley, SL, Katlama, C. and Clotet, B. (2006) Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from 2 randomized open-label trials. Lancet, 368, pp. 466-475.
33. Youle, M., Staszweski, S., Clotet, B., Arribas, JR, Blaxhult, A. and Carosi, G. (2006) Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: Recent data and consensus recommendations. HIV Clin Trials, 7, pp. 86-96.
34. Nelson, M., Arasteh, K., Clotet, B., Cooper, DA, Henry, K. and Katlama, C. (2005) Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr, 40, pp. 404-412.
35. Naver, L., Lindgren, S., Belfrage, E., Gyllensten, K., Lidman, K. and Gisslen, M. (2006) Children born to HIV-1-infected women in Sweden in 1982-2003: Trends in epidemiology and vertical transmission. J Acquir Immune Defic Syndr, 42, pp. 484-489.
36. McIntosh, K., Shevitz, A., Zaknun, D., Kornegay, J., Chatis, P. and Karthas, N. (1996) Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J, 15, pp. 1087-1091.
37. (1992) Age-related standards for T-lymphocyte subsets based on uninfected children born to human immunodeficiency virus 1-infected women. The European Collaborative Study. Pediatr Infect Dis J, 11, pp. 1018-1026.
38. Dunn, D. (2003) Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet, 362, pp. 1605-1611.
39. Sharland, M., Blanche, S., Castelli, G., Ramos, J. and Gibb, DM. (2004) PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med, 5, pp. 61-86.
40. McComsey, GA and Leonard, E. (2004) Metabolic complications of HIV therapy in children. Aids, 18, pp. 1753-1768.
41. Smith, DE, Walker, BD, Cooper, DA, Rosenberg, ES and Kaldor, JM. (2004) Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence?. Aids, 18, pp. 709-718.
42. Goh, LE, Perrin, L., Hoen, B., Cooper, D., Phillips, A. and Janossy, G. (2001) Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study. HIV Clin Trials, 2, pp. 438-444.
43. Nilsson, J., Kinloch-de-Loes, S., Granath, A., Sonnerborg, A., Goh, LE and Andersson, J. (2007) Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. Aids, 21, pp. 565-574.
44. Apetrei, C., Tamalet, C., Edlinger, C., Damond, F., Descamps, D. and Saimot, AG (1998) Delayed HIV-1 seroconversion after antiretroviral therapy. Aids, 12, pp. 1935-1936.
45. Telzir, SPC and Glaxo
46. Sulkowski, MS. (2006) Treatment algorithm for the management of hepatitis C in HIV-coinfected persons. J Hepatol, 44, p. S49.
47. Alberti, A., Clumeck, N., Collins, S., Gerlich, W., Lundgren, J. and Palu, G. (2005) Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV coinfected patients. J Hepatol, 42, pp. 615-624.
48. Rey, D., Krantz, V., Partisani, M., Schmitt, MP, Meyer, P. and Libbrecht, E. (2000) Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine, 18, pp. 1161-1165.
49. Chesney, MA, Ickovics, JR, Chambers, DB, Gifford, AL, Neidig, J. and Zwickl, B. (2000) Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12, pp. 255-266.
50. Hecht, FM. (1998) Measuring HIV treatment adherence in clinical practice. AIDS Clin Care, 10, pp. 57-59.
51. Mellors, JW, Rinaldo Jr, CR, Gupta, P., White, RM, Todd, JA and Kingsley, LA. (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 272, pp. 1167-1170.
52. Katzenstein, TL, Ullum, H., Roge, BT, Wandall, J., Dickmeiss, E. and Barrington, T. (2003) Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 months. HIV Med, 4, pp. 53-61.
53. Devereux, HL, Youle, M., Johnson, MA and Loveday, C. (1999) Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. Aids, 13, p. F123.
54. Izopet, J., Massip, P., Souyris, C., Sandres, K., Puissant, B. and Obadia, M. (2000) Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. Aids, 14, pp. 2247-2255.
55. Verhofstede, C., Wanzeele, FV, van der Gucht, B., De Cabooter, N. and Plum, J. (1999) Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. Aids, 13, pp. 2541-2546.
56. Miller, V., Sabin, C., Hertogs, K., Bloor, S., Martinez-Picado, J. and D'Aquila, R. (2000) Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. Aids, 14, pp. 2857-2867.
57. Deeks, SG, Wrin, T., Liegler, T., Hoh, R., Hayden, M. and Barbour, JD (2001) Virological and immunological consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viraemia. N Engl J Med, 344, pp. 472-480.
58. Khoo, SH, Lloyd, J., Dalton, M., Bonington, A., Hart, E. and Gibbons, S. (2006) Pharmacological optimization of protease inhibitors and non-nucleoside reverse transcriptase inhibitors (POPIN): A randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr, 41, pp. 461-467.
59. Viread, SPC
60. Moreno, A., Quereda, C., Moreno, L., Perez-Elias, MJ, Muriel, A. and Casado, JL (2004) High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther, 9, pp. 133-138.
61. Alvarez, D., Dieterich, DT, Brau, N., Moorehead, L., Ball, L. and Sulkowski, MS. (2006) Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat, 13, pp. 683-689.
62. Rendon, AL, Nunez, M., Romero, M., Barreiro, P., Martin-Carbonero, L. and Garcia-Samaniego, J. (2005) Early monitoring of ribavirin plasma concentrations may predict anaemia and early virological response in HIV/ hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr, 39, pp. 401-405.
63. Aptivus, SPC
64. Reyataz, SPC
65. Ouellet, D., Hsu, A., Qian, J., Locke, CS, Eason, CJ and Cavanaugh, JH (1998) Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol, 46, pp. 111-116.
66. Piscitelli, SC, Burstein, AH, Chaitt, D., Alfaro, RM and Falloon, J. (2000) Indinavir concentrations and St John's wort. Lancet, 355, pp. 547-548.
67. van der Valk, M., Casula, M., Weverlingz, GJ, van Kuijk, K., van Eck-Smit, B. and Hulsebosch, HJ (2004) Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther, 9, pp. 385-393.
68. Moyle, G. and Sutinen, J. (2004) Managing HIV lipoatrophy. Lancet, 363, pp. 412-414.
69. Moyle, GJ. (2005) The role of zidovudine in development of lipoatrophy. AIDS Read, 15, pp. 591-4, 599-600, 603.
70. Birkus, G., Hitchcock, MJ and Cihlar, T. (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother, 46, pp. 716-723.
71. Martin, A., Smith, DE, Carr, A., Ringland, C., Amin, J. and Emery, S. (2004) Reversibility of lipoatrophy in HIV-infected patients 2 y after switching from a thymidine analogue to abacavir: The MITOX Extension Study. Aids, 18, pp. 1029-1036.
72. McComsey, GA, Ward, DJ, Hessenthaler, SM, Sension, MG, Shalit, P. and Lonergan, JT (2004) Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis, 38, pp. 263-270.
73. Moyle, GJ, Sabin, CA, Cartledge, J., Johnson, M., Wilkins, E. and Churchill, D. (2006) A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. Aids, 20, pp. 2043-2050.
74. Podzamczer, D., Ferrer, E., Sanchez, P., Gatell, JM, Crespo, M. and Fisac, C. (2007) Less lipoatrophy and better lipid profile with abacavir compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr, 44, pp. 139-147.
75. Mallon, PW, Miller, J., Cooper, DA and Carr, A. (2003) Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. Aids, 17, pp. 971-979.
76. Connolly, N., Manders, E. and Riddler, S. (2004) Suction-assisted lipectomy for lipodystrophy. AIDS Res Hum Retroviruses, 20, pp. 813-815.
77. Sax, PE. (2006) Strategies for management and treatment of dyslipidaemia in HIV/AIDS. AIDS Care, 1, pp. 149-157.
78. Mobius, U., Lubach-Ruitman, M., Castro-Frenzel, B., Stoll, M., Esser, S. and Voigt, E. (2005) Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidaemia. J Acquir Immune Defic Syndr, 39, pp. 174-180.
79. Noor, MA, Flint, OP, Maa, JF and Parker, RA. (2006) Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: Demonstrable differences in vitro and clinically. Aids, 20, pp. 1813-1821.
80. Jones, R., Sawleshwarkar, S., Michailidis, C., Jackson, A., Mandalia, S. and Stebbing, J. (2005) Impact of antiretroviral choice on hypercholesterolaemia events: The role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med, 6, pp. 396-402.
81. Gallant, JE, Staszewski, S., Pozniak, AL, DeJesus, E., Suleiman, JM and Miller, MD (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-y randomized trial. JAMA, 292, pp. 191-201.
82. Brown, TT, Cole, SR, Kingsley, LA, Palella, FJ and Riddler, SA (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicentre AIDS cohort study. Arch Intern Med, 165, pp. 1179-1184.
83. Friis-Moller, N., Sabin, CA, Weber, R., Monforte, A d'Arminio, El-Sadr, WM and Reiss, P. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med, 349, pp. 1993-2003.
84. Keiser, PH, Sension, MG, DeJesus, E., Rodriguez, A., Olliffe, JF and Williams, VC (2005) Substituting abacavir for hyperlipidaemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virological suppression, and simplifies treatment. BMC Infect Dis, 5, p. 2.
85. Llibre, JM, Domingo, P., Palacios, R., Santos, J., Perez-Elias, MJ and la Rosa, R Sanchez-de (2006) Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. Aids, 20, pp. 1407-1414.
86. Fichtenbaum, CJ, Gerber, JG, Rosenkranz, SL, Segal, Y., Aberg, JA and Blaschke, T. (2002) Pharmacokinetic interactions between protease inhibitors and statins in HIV-seronegative volunteers: ACTG Study A5047. Aids, 16, pp. 569-577.
87. Hsyu, PH, Schultz-Smith, MD, Lillibridge, JH, Lewis, RH and Kerr, BM. (2001) Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother, 45, pp. 3445-3450.
88. Prezista, SPC
89. Carr, A. (2003) Lactic acidaemia in infection with human immunodeficiency virus. Clin Infect Dis, 36, p. S96.
90. Arenas-Pinto, A., Grant, AD, Edwards, S. and Weller, IV. (2003) Lactic acidosis in HIV-infected patients: A systematic review of published cases. Sex Transm Infect, 79, pp. 340-343.
91. Geddes, R., Knight, S., Moosa, MY, Reddi, A., Uebel, K. and Sunpath, H. (2006) A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J, 96, pp. 722-724.
92. Lonergan, JT, Barber, RE and Mathews, WC. (2003) Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactataemia and lactic acidosis. Aids, 17, pp. 2495-2499.
93. Servoss, JC, Kitch, DW, Andersen, JW, Reisler, RB, Chung, RT and Robbins, GK. (2006) Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr, 43, pp. 320-323.
94. Nunez, M. and Soriano, V. (2005) Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf, 28, pp. 53-66.
95. Zimmermann, AE, Pizzoferrato, T., Bedford, J., Morris, A., Hoffman, R. and Braden, G. (2006) Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis, 42, pp. 283-290.
96. Gallant, JE, Parish, MA, Keruly, JC and Moore, RD. (2005) Changes in renal function associated with tenofovir disoproxil fumarate treatment compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis, 40, pp. 1194-1198.
97. Winston, A., Amin, J., Mallon, P., Marriott, D., Carr, A. and Cooper, DA (2006) Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med, 7, pp. 105-111.
98. Crixivan, SPC Merck, Sharp and Dohme.
99. Boyd, MA, Siangphoe, U., Ruxrungtham, K., Reiss, P., Mahanontharit, A. and Lange, JM (2006) The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J Antimicrob Chemother, 57, pp. 1161-1167.
100. Dieleman, JP, Gyssens, IC, van der Ende, ME, de Marie, S. and Burger, DM. (1999) Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. Aids, 13, pp. 473-478.
101. Viramune, SPC Boehringer Ingelheim.
102. Ziagen, SPC Glaxo.
103. Clay, PG. (2002) The abacavir hypersensitivity reaction: A review. Clin Ther, 24, pp. 1502-1514.
104. Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, AM and Moore, C. (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 359, pp. 727-732.
105. Martin, AM, Nolan, D., Gaudieri, S., Almeida, CA, Nolan, R. and James, I. (2004) Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A, 101, pp. 4180-4185.
106. (1994) Revised classification system for HIV infection in children less than 13 y of age. MMWR Morbidity and mortality weekly report 1994, 43, pp. 1-10.